Gilead Says Remdesivir Will Change Congress’ Attitude On Drug Prices

Gilead executives said they are already seeing lawmakers change their attitudes toward drug price controls as drug makers develop desperately needed drugs and vaccines against COVID-19. “The tone is different in Washington,” Gilead CEO Daniel O’Day said Thursday (April 30) during a first quarter earnings call. The call came a day after the company announced promising initial results from clinical trials of its antiviral remdesivir in treating COVID-19. Company executives hope to make enough of the drug to treat 1...